Takeda Names Successor to Retiring CEO in 2026
Takeda has announced that its Board of Directors made the decision unanimously to appoint Julie Kim, currently President of Takeda’s US Business Unit, as the successor to Christophe Weber, Takeda’s current President, Chief Executive Officer (CEO), and Representative Director, when Weber retires from the company in June 2026.
Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareholders Meeting to be held in June 2026. Weber will not hold a Board seat after retiring from Takeda.
Kim has been the President of the US Business Unit and US country head since 2022, and has been a member of the Takeda Executive Team since 2019. With three decades of experience in healthcare, Kim has held leadership positions at global, regional, country, and functional levels in roles covering a range of therapeutic areas, international market access, general management, marketing, and emerging market development.
Weber joined Takeda in June 2014 as Chief Operating Officer. He was name President and Representative Director in June 2014 and subsequently appointed CEO in June 2015. Noteworthy strategic moves by Weber included Takeda’s $62-billion acquisition of Shire Pharmaceuticals in 2019.
Source: Takeda